maintain buy pt
overal quarter strong report top-lin
result slightli ahead model rtg exceed street
earn beat consensu three cent spine saw meaning upsid
offset softer-than-expect cardiovascular result thank ou growth
diabet came slightli ahead expect said seem
competit challeng innov gap near-term rein
momentum remaind may bother investor
oper execut consist streamlin program continu
deliv sg flattish despit revenue growth cash flow robust
y/i tax rate came plan lead ep upsid
turn pipelin import timelin unchang bolu new
launch kick start hot topic robot littl
new plan submit eu gain approv
overal remain posit stori base encourag pipelin
back half cvg disrupt subsid attract valuat
structur advantag afford solid balanc sheet remain key
differenti especi economi worsen investor shift away risk
maintain buy rate pt
continu drive pull-through capit equip side fuel best
growth spine recent year includ enabl tech spine grew
impress pain remain bit pain pun intend
market remain soft next-gen iter earli calendar may help
outperform though seem payor scrutini remain issu regard tavr
earli adopt pro valv encourag buoy ww tavr growth
even evolut cede share lotu quarter
though seem lotu overal gain still fairli modest lastli near-term
diabet outlook remain bleak surpris sizabl cut
expect seem turnaround larg depend
tweak forecast lift revenu growth forecast slightli
maintain oper margin forecast
better sg trend off-set lighter gross margin perform net-net
adj ep move
valuat pt base month ep estim
target multipl mirror current multipl ntm ep forecast risk
page
idc btig estim compani document
million except per share amount
medtron rate buy believ qualiti pipelin launch nearli everi product segment posit
compani well improv growth start back half meanwhil introduct robot platform
provid increment revenu stream final compani strong track record free cash flow gener offer
consider cushion earn growth
stabl procedur growth price
expans current tam
cut reimburs
neg chang regul
one largest
diversifi compani
med-tech sell product
cardiac vascular group
restor therapi diabet
consolid revenu slightli ahead forecast report segment except cvg came ahead
consensu spine biggest standout constant currenc basi rtg growth driven low-
double-digit improv brain therapi mid-single-digit growth spine specialti therapi low-single-digit
growth pain therapi turn mitg revenu growth reflect mid-single-digit growth across
si diabet revenu growth also bit better model although us growth declin high-
singl digit due competit challeng off-set intern growth final cvg y/i
improv fuel high-single-digit growth csh off-set low-single-digit decreas crhf flat
result apv
gross margin weaker forecast due impact fx smaller impact
china tariff sg margin better model margin line
forecast overal ebit margin better estim line interest expens came lower
forecast follow refinanc effort tax rate also well estim told adj ep
came estim
actualsbtig estimate varianceww cardiac rhythm hf cardiac vascular group minim spine restor therapi diabet net bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
fiscal tweak revenu growth better trend within
segment rais rtg estim trim diabet forecast substanti report
basi model revenu growth oper margin tweak gross margin lag trend
first half improv sg margin assumpt go forward lastli reduc forecast tax rate
full year consist trend seen first half new adj ep estim
medtron rate buy pt base share trade month ep estim target
multipl similar current multipl ntm earn believ qualiti pipelin launch nearli everi
product segment posit compani well acceler revenu growth start back half meanwhil
introduct robot platform offer increment revenu stream final compani strong track record
free cash flow gener offer consider cushion earn growth risk includ deterior cardiac market
delay robot launch advers tax propos soft emerg market margin degrad expans
new busi line competit slippag product timelin chang procedur reimburs futur devic
data fda use cash/m tariff possibl multipl contract
exhibit comp tabl large-cap med-tech compani
bpsc growth bpsadj net bpsgross bpsebit bp btig estim compani filingsnewold changentm johnsonjnjnot bdxnot scientificbsxbuy factset data btig estimatesintra-day price ex-amortcompanytickr ptpricemarket cap
medtron incom eproduct net y/i good gross total oper oper expens adj oper interest expens non-oper expense/ inc pre-tax incom adj net non-controlling adj net incom adjust ep share total net oper net product product product oper btig estim compani report
medtron revenu model ecrm heart failur structur heart y/i peripher vascular total recast y/i vascular group y/i patient monitor recoveri y/i invas therapi group y/i recast therapi recast therapi recast therapi recast therapi group y/i group y/i y/i oper y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
